Keros Therapeutics, Inc. (KROS)
10.78
-0.25
(-2.27%)
USD |
NASDAQ |
Aug 24, 16:00
10.79
+0.01
(+0.09%)
Pre-Market: 20:00
Keros Therapeutics Profit Margin (Quarterly)
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -6.46K% |
| December 31, 2025 | -6.09K% |
| September 30, 2025 | -51.04% |
| June 30, 2025 | -169.0% |
| March 31, 2025 | 70.27% |
| December 31, 2024 | -1.51K% |
| September 30, 2024 | -13.65K% |
| June 30, 2024 | -122.3K% |
| March 31, 2024 | -51.94K% |
| December 31, 2023 | -28.14K% |
| September 30, 2023 | -493.0K% |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 |
| Date | Value |
|---|---|
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | -34.70% |
| September 30, 2021 | |
| June 30, 2021 | -15.62K% |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -110.0% |
| September 30, 2019 | -142.0% |
| June 30, 2019 | -114.1% |
| March 31, 2019 | -127.3% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Incyte Corp. | 34.98% |
| Nurix Therapeutics, Inc. | -990.1% |
| ACADIA Pharmaceuticals, Inc. | 10.23% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Anika Therapeutics, Inc. | 10.15% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -18.39% |
| Return on Assets | -17.02% |
| Return on Invested Capital | -17.73% |
| Return on Net Operating Assets | -226.8% |